Bernstein Harold 4

4 · Maze Therapeutics, Inc. · Filed Jun 3, 2026

AI-generated summary of this filing

Updated Jun 3, 2026

Maze Therapeutics (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened

Harold Bernstein, President R&D & Chief Medical Officer at Maze Therapeutics, exercised 14,853 stock options and sold all 14,853 resulting shares on June 1, 2026. He paid $10.42 per share on exercise (total cost $154,768) and sold the shares in two blocks for total proceeds of $381,112 (13,253 shares at a weighted avg $25.57 for $338,940; 1,600 shares at a weighted avg $26.36 for $42,172). Net proceeds (sale proceeds minus exercise cost) were about $226,344. These sales were executed under a pre-established 10b5-1 trading plan.

Key Details

Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (period of report June 1, 2026).
Exercise: 14,853 shares at $10.42 each — $154,768 total (code M).
Sales: 13,253 shares at weighted avg $25.57 (sales ranged $25.16–$26.10) and 1,600 shares at weighted avg $26.36 (sales ranged $26.16–$26.53); total proceeds $381,112.
A reported derivative disposition at $0 reflects the conversion/exercise of the option into shares.
Footnote: Sales effected pursuant to a Rule 10b5-1 plan adopted Sept 29, 2025; weighted-average sale prices reported with ranges (per filing).
Shares owned after the transactions: not specified in the provided filing.
Filing timeliness: no late filing flag indicated.

Context

This was effectively a cashless exercise followed by immediate open-market sales (common for option holders to cover exercise cost/taxes or monetize gains). The presence of a 10b5-1 plan means the sales were prearranged. The option vesting schedule noted in the filing: 1/4 vested Oct 3, 2023, with the remainder vesting monthly (1/48th) thereafter, subject to continued service.

Form 4

Period: 2026-06-01

President, R&D & CMO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-01$10.42/sh+14,853$154,768→ 14,853 total
Sale
Common Stock
[F1][F2]
2026-06-01$25.57/sh−13,253$338,940→ 1,600 total
Sale
Common Stock
[F1][F3]
2026-06-01$26.36/sh−1,600$42,172→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-01−14,853→ 207,554 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (14,853 underlying)

Footnotes (4)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive.
[F4]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-06-03

1 file